Ahmad Masri (@masriahmadmd) 's Twitter Profile
Ahmad Masri

@masriahmadmd

@OHSUCardio | #HCM #Amyloid #Fabry #LVH #DCM #Cardiomyopathies #Cardiogenetics #Echofirst #WhyCMR #CVNuc #RCTs | Views are mine & not medical advice

ID: 2456288524

linkhttps://www.ohsu.edu/people/ahmad-masri-md-ms calendar_today03-04-2014 00:13:40

23,23K Tweet

8,8K Followers

991 Following

Giuseppe Biondi-Zoccai (@gbiondizoccai) 's Twitter Profile Photo

In the SEQUOIA-HCM RCT, adult patients with symptomatic obstructive hypertrophic cardiomyopathy receiving aficamten demonstrated significant improvement in LVOT gradients and measures of LV diastolic function in comparison to those receiving placebo, and these changes were

In the SEQUOIA-HCM RCT, adult patients with symptomatic obstructive hypertrophic cardiomyopathy receiving aficamten demonstrated significant improvement in LVOT gradients and measures of LV diastolic function in comparison to those receiving placebo, and these changes were
Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

#ESCCONGRESS was a phenomenal meeting with lots of great science in #amyloid #HCM and #cardiomyopathies And visiting Oxford and JR was the icing on the cake. Thanks Betty Raman Christopher Toepfer et al for a memorable time

#ESCCONGRESS was a phenomenal meeting with lots of great science in #amyloid #HCM and #cardiomyopathies 

And visiting Oxford and JR was the icing on the cake. Thanks <a href="/BR_CMR/">Betty Raman</a> <a href="/ChrisToepfer/">Christopher Toepfer</a> et al for a memorable time
Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

A milestone in #transthyretin #amyloidosis ACT-EARLY kicks off - acoramidis vs placebo for the prevention of #ATTR phenotype in patients at risk. clinicaltrials.gov/study/NCT06563… investor.bridgebio.com/static-files/6… #CardioTwitter

A milestone in #transthyretin #amyloidosis 

ACT-EARLY kicks off - acoramidis vs placebo for the prevention of #ATTR phenotype in patients at risk. 

clinicaltrials.gov/study/NCT06563…

investor.bridgebio.com/static-files/6…

#CardioTwitter
Betty Raman (@br_cmr) 's Twitter Profile Photo

Thanks Ahmad for giving a terrific talk RDM Oxford! It was amazing to hear about your exciting research in HCM and look forward to inviting you over again to hear about the incredible progress you will have made in this space.

HCPLive (@hcplivenews) 's Twitter Profile Photo

From #ESCCongress: In our third interview segment with Ahmad Masri, he highlighted a trio of aficamten-related studies providing insight into the effects of the cardiac myosin inhibitor in patients with oHCM. hcplive.com/view/aficamten… #Cardiomyopathy Cytokinetics

ASNC Society (@myasnc) 's Twitter Profile Photo

🎉#ASNC2024 is already in the Top 10 trending conferences on Symplur, and the meeting hasn't even started yet!📈 Excited by the buzz🐝 and can't wait for it to kick off tomorrow! #CVNuc #CardioTwitter #Austin #Texas

🎉#ASNC2024 is already in the Top 10 trending conferences on <a href="/symplur/">Symplur</a>, and the meeting hasn't even started yet!📈

Excited by the buzz🐝 and can't wait for it to kick off tomorrow! #CVNuc #CardioTwitter #Austin #Texas
Greg Lewis (@glewiscardiol) 's Twitter Profile Photo

Published today in JAMA Cardiology. Cardiopulmonary Exercise Testing (#CPET) in clinical trials captures ∆es in ex. performance. In #oHCM, aficamten ↑peak VO2, ↑workload, ↑cardiac power, ↑ VO2 at AT & improved ventilatory efficiency. Our novel z-score integrating ∆pVO2 and

Martin Maron, MD (@martinmaronmd) 's Twitter Profile Photo

What’s next for clinical trials in #HCM? Join Rosalyn Adigun, M.D., Pharm.D., M.Sc. & #JamesUdelson on October 27 at #HCMSummit8 to discover the future of research & how it will shape patient care. Secure your spot today: hcmsummit.org #hypertrophiccardiomyopathy #cardiotwitter #cardioed #cardiox

What’s next for clinical trials in #HCM? Join <a href="/radigun1/">Rosalyn Adigun, M.D., Pharm.D., M.Sc.</a> &amp; #JamesUdelson on October 27 at #HCMSummit8 to discover the future of research &amp; how it will shape patient care. Secure your spot today: hcmsummit.org #hypertrophiccardiomyopathy #cardiotwitter #cardioed #cardiox
Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

Look at mortality in these groups. I wondered how did this trial continue? Investigators employed response-adaptive randomization strategy - see 2nd screenshot #CardioTwitter

Look at mortality in these groups. I wondered how did this trial continue? 

Investigators employed response-adaptive randomization strategy - see 2nd screenshot 

#CardioTwitter
Cornerstone Medical Education (@cornerstone_cme) 's Twitter Profile Photo

On the heels of a stellar and eventful #ESC where #amyloid featured prominently, our #ATTR #FinalFour Young Investigators have been decided! Official announcement coming TOMORROW! Ahmad Masri Amyloidosis Speakers Bureau Amyloidosis Research Consortium